CC
Casdin Capital, LLC
OFFICER
内部人交易记录
其他基于 7 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the full record of transactions filed by Casdin Capital, LLC. Officer active across 2 companies, notably GeneDx Holdings Corp.. Aggregated, 13 reports have been published. Split: 9 buys · 1 sell. Total volume traded: €67.4m. History available since 4 March 2024. The latest transaction was disclosed on 5 June 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Casdin Capital, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报13 总计
150,000 股@ US$56.44490.36% mcap27.9% 占其流量Class A Common Stock, par value $0.0001 per shareSEC:0000919574-26-003907:0
50,000 股@ US$52.85660.11% mcap8.7% 占其流量Class A Common Stock, par value $0.0001 per shareSEC:0000919574-26-003907:1
500,000 股@ US$120.903966.6% 占其流量Class A Common StockSEC:0000919574-25-005084:0
22,625 股@ US$5.006.2% 占其流量Common Stock, par value $0.0001 per shareSEC:0000919574-25-003264:0
413,655 股@ US$32.2574.5% 占其流量Class A Common StockSEC:0000919574-24-004273:0
6,025 股Common Stock, par value $0.0001 per shareSEC:0000919574-24-003576:0
100,000 股@ US$20.816411.5% 占其流量Class A Common StockSEC:0000919574-24-003510:0
40,000 股@ US$21.06514.7% 占其流量Class A Common StockSEC:0000919574-24-003432:0
7,500 股@ US$19.58880.8% 占其流量Class A Common StockSEC:0000919574-24-003355:0
50,000 股@ US$23.30596.5% 占其流量Class A Common StockSEC:0000919574-24-003212:0
40,000 股@ US$5.099811.5% 占其流量Common Stock, par value $0.0001 per shareSEC:0000919574-24-002241:0
300,000 股@ US$4.903382.3% 占其流量Common Stock, par value $0.0001 per shareSEC:0000919574-24-002176:0
40,000 股@ US$8.74271.9% 占其流量Class A Common StockSEC:0000919574-24-001889:0
About Casdin Capital, LLC
Casdin Capital, LLC is a declarant linked to 13 filings in total. Among the 13 sampled recent filings between 2024-03-06 and 2026-06-08, the reported amounts are EUR 15325043 of buys and EUR 52055174 of sells, with transactions involving GeneDx Holdings Corp. and 2seventy bio, Inc., and the modal transaction nature is Acquisition. It is listed as Director at GeneDx Holdings Corp. and at 2seventy bio, Inc.